Nano-drug based on dendrimer and application thereof
By combining dasatinib and epirubicin with dendritic macromolecules, a controlled degradable dendritic nanodrug was solved, and the problem of ECM barrier hindering drug delivery was achieved efficiently inhibiting tumor growth in breast cancer and Transfer and have no toxic side effects.
Patent Information
- Application Number
- CN202410991990.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-01
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-08
AI Technical Summary
The efficacy of existing therapeutic drugs in solid tumors is hindered by the extracellular matrix (ECM) barrier, especially in breast cancer, where dense ECM layers hinder nanodrug penetration and tumor delivery, and uncontrollable ECM degradation exists Immune response and tumor metastasis risk.
Develop dendritic macromolecules based on dendritic polymers, dasatinib (DAS) and epirubicin (Epi) dendritic macromolecules, coupled to dendritic structures through enzyme-responsive polymers, enhancing them to cell membranes and endoplasmic reticulum The interactions of the cells promote internalization and achieve controllable ECM remodeling to improve drug permeability through ECM-specific enzyme degradation.
It significantly improves the ability of dasatinib and epirurubicin to inhibit cancer cell proliferation, inhibit tumor metastasis, and further improves the tumor inhibition effect in vivo when used in combination, without obvious toxic side effects, and has excellent application prospects.
Smart Images

Figure CN118903452A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine, and in particular relates to nano medicine based on dendrimer and application thereof. Background Art
[0002] Dense extracellular matrix (ECM), high interstitial pressure (IFP) and abnormal vascular system constitute a complex tumor microenvironment (TME), which significantly weakens the efficacy of therapeutic drugs in solid tumors. Due to the composition and mechanical properties of ECM, it promotes tumor progression and metastasis and hinders the delivery of therapeutic drugs to solid tumors. Therefore, overcoming the ECM barrier is an effective strategy to enhance drug penetration into solid tumors, which is crucial to improve therapeutic efficacy.
[0003] In stroma-rich breast cancer, cancer-associated fibroblasts (CAFs), which are transformed from normal fibroblasts through pro-fibrotic signaling pathways, account for a large proportion of the tumor volume and play a key role in tumor progression and invasion. ECM proteins secreted by CAFs interact with each other to form a dense ECM layer, which protects tumors from immune cell attacks and hinders the penetration of nanomedicines. In addition, metabolites produced by CAFs metabolic pathways contribute to the establishment of an immunosuppressive microenvironment, thereby complicating therapeutic strategies. However, indiscriminate depletion of CAFs often leads to the release of growth factors and cytokines, which may trigger tumor progression and migration. Therefore, precise regulation of CAFs to reshape the ECM is an important research topic in this field to improve the efficacy of nanomedicines.
[0004] There are reports on the use of dasatinib (DAS) and epirubicin (Epi) in the treatment of breast cancer, but their tumor-suppressing effects in vivo need to be further improved.
[0005] In recent years, the research on nanomedicine has led to the development of a variety of strategies to enhance drug tumor penetration, including regulating the size, charge, structure and surface properties of nanoparticles to overcome the physical, chemical and biological barriers encountered in the process of delivering nanoparticles into solid tumors. Dendrimers have attracted much attention among these strategies because of their unique structure that can produce multivalent effects. For example, after the amphiphilic enzyme-responsive polymer-dendritic drug conjugates are cleaved by enzymes in the TME, the dendritic structural units are released, thereby enhancing their interaction with the cell membrane and endoplasmic reticulum, promoting their cellular internalization and penetrating into solid tumors. Nanocarriers can degrade ECM by delivering ECM-specific enzymes. However, due to uncontrollable ECM degradation, there is a risk of immune response and tumor metastasis. Therefore, it is necessary to study a nanodrug delivery strategy that can controllably regulate tumor ECM, thereby overcoming the ECM barrier and effectively promoting drug penetration into tumors, while minimizing the side effects associated with ECM consumption. Summary of the invention
[0006] The object of the present invention is to provide nanomedicine based on dendrimer and application thereof.
[0007] The present invention provides a dasatinib dendrimer drug, the structure of which is shown in Formula I:
[0008]
[0009] Among them, x is 30-60; y is 0.1-5;
[0010] The content of dasatinib in the dasatinib dendrimer drug is 3-10 wt %.
[0011] Furthermore, the weight average molecular weight of the dasatinib dendrimer drug is 30-45 kg mol -1 , x is 45-52, y is 0.5-2.5, and the content of dasatinib in the dasatinib dendrimer drug is 5.5wt%.
[0012] The present invention also provides an epirubicin dendrimer drug, characterized in that it is a product prepared by sequentially reacting the compound represented by formula II with tricarboxyethylphosphine and Mal-Epi;
[0013] The structure of the compound shown in formula II is as follows:
[0014]
[0015] Wherein, m is 40-80; n is 0.1-4;
[0016] The structure of Mal-Epi is as follows:
[0017] The content of epirubicin in the epirubicin dendrimer drug is 3-12 wt %.
[0018] Furthermore, the weight average molecular weight of the epirubicin dendrimer drug is 30-45 kg mol -1 ;
[0019] In the compound represented by formula II, m is 50-60, and n is 0.5-2.2;
[0020] The mass ratio of the compound represented by formula II, tricarboxyethylphosphine, and Mal-Epi is 44:44:17;
[0021] The reaction temperature is 20-35°C and the reaction time is 20-30 hours;
[0022] The content of epirubicin in the epirubicin dendrimer drug is 6.9 wt%.
[0023] The present invention also provides a combined drug with anti-tumor effect, which contains dasatinib dendrimer drug and epirubicin dendrimer drug of the same or different specifications for simultaneous or separate administration, and a pharmaceutically acceptable carrier; wherein the mass ratio of dasatinib in the dasatinib dendrimer drug to epirubicin in the epirubicin dendrimer drug is (1-2): (1-2).
[0024] Furthermore, the mass ratio of dasatinib in the dasatinib dendrimer drug to epirubicin in the epirubicin dendrimer drug is 1:1.
[0025] Furthermore, it also contains anti-PD-1 antibodies for simultaneous or separate administration in unit preparations of the same or different specifications, wherein the mass ratio of the anti-PD-1 antibody to epirubicin in the epirubicin dendrimer drug is (3-10):(5-20).
[0026] Furthermore, the mass ratio of the anti-PD-1 antibody to epirubicin in the epirubicin dendrimer drug is 5:8.
[0027] The present invention also provides a use of the above-mentioned dasatinib dendrimer drug, the above-mentioned epirubicin dendrimer drug, and the above-mentioned combined drug in the preparation of drugs for treating tumors and / or inhibiting tumor metastasis.
[0028] Furthermore, the tumor is breast cancer.
[0029] Furthermore, in the combined drug of the unit preparation, the content of Epi is greater than 0.2 μg.
[0030] In the present invention, the polymer is a mixture of molecules of different molecular weights, and therefore, "x", "y", "m", and "n" indicating the number of repeating units are average values.
[0031] In summary, the present invention provides nanomedicines based on dendrimers and their applications. By combining DAS and Epi with different dendrimers, the present invention synthesizes two nanomedicines P-DAS and P-Epi. P-DAS and P-Epi significantly improve the ability of DAS and Epi to inhibit the proliferation of cancer cells. At the same time, when P-DAS is used in combination with P-Epi, the tumor inhibition effect in vivo is more excellent, and tumor metastasis can be inhibited. When P-DAS, P-Epi and anti-PD-1 antibodies are used in combination, the tumor inhibition effect in vivo is further improved, and there are no obvious toxic and side effects. The present invention has excellent application prospects in inhibiting breast cancer tumors and inhibiting tumor metastasis.
[0032] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0033] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 This is a synthetic route for methacrylate monomers.
[0035] Figure 2 This is the H NMR spectrum of compound MA-PEG5-Lys(G2)-4Alkynyl in deuterated DMSO.
[0036] Figure 3 This is the H NMR spectrum of compound MA-PEG5-Lys(G2)-4SSPy in deuterated DMSO.
[0037] Figure 4 This is the synthetic route of N3-GFLG-DAS.
[0038] Figure 5 This is the H NMR spectrum of compound N3-GFLG-DAS in deuterated DMSO.
[0039] Figure 6 This is the synthetic route of POEGMA-4Alkynyl and POEGMA-4SSPy.
[0040] Figure 7 This is the H NMR spectrum of polymer POEGMA-4Alkynyl in deuterated DMSO.
[0041] Figure 8 This is the H NMR spectrum of polymer POEGMA-4SSPy in deuterated DMSO.
[0042] Fig. 9 For P-DAS, Cy5 Synthetic routes of P-DAS and P-Epi.
[0043] Fig.10 This is the H-NMR spectrum of polymer P-DAS in deuterated DMSO.
[0044] Fig.11 This is the H-NMR spectrum of polymer P-Epi in deuterated DMSO.
[0045] Fig.12 UV absorption spectra of DAS, N3-GFLG-DAS and P-DAS.
[0046] Fig.13 Ultraviolet absorption spectra of Epi, Mal-Epi and P-Epi.
[0047] Fig.14 The UV absorption spectra and standard curves of DAS with different concentrations in DMSO solution are shown in Figure 2.
[0048] Fig.15 Shows the UV absorption spectra and standard curves of different concentrations of Epi in DMSO solution.
[0049] Fig.16 Zeta potential of P-DAS and P-Epi
[0050] Fig.17 is the hydrated particle size of P-DAS and P-Epi
[0051] Fig.18 The graph shows the maturation results of DCs after incubation with various drugs.
[0052] Fig.19 The maturation statistics of DCs after incubation with various drugs are shown in Figure 2 .
[0053] Fig. 20 The cytotoxicity of P-DAS→P-Epi to 4T1 cells
[0054] Fig.21 It is the combined index of P-DAS and P-Epi.
[0055] Fig. 22 This is the anti-tumor curve of 4T1 tumor-bearing mice.
[0056] Fig.23 is the tumor inhibition rate of 4T1 tumor-bearing mice.
[0057] Fig.24 The figure shows lung metastasis in 4T1 tumor-bearing mice.
[0058] Fig.25 This is the anti-tumor curve of P-DAS→P-Epi combined with anti-PD-1 antibody in 4T1 tumor-bearing mice.
[0059] Fig.26 This is the tumor inhibition rate of P-DAS→P-Epi combined with anti-PD-1 antibody in 4T1 tumor-bearing mice.
[0060] Fig. 27 The survival period of P-DAS→P-Epi combined with anti-PD-1 antibody in 4T1 tumor-bearing mice.
[0061] Fig.28 The figure shows the weight changes of 4T1 tumor-bearing mice after treatment with P-DAS→P-Epi combined with anti-PD-1 antibody. DETAILED DESCRIPTION
[0062] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.
[0063] Py-SS-COOH:CAS:68617-64-1
[0064] N3-GFLG-COOH:CAS:2089436-65-5
[0065] Oligo(ethylene glycol)methyl methacrylate (OEGMA, MW=500) was purchased from Sigma-Aldrich (Product No. 447943).
[0066] Example 1. Preparation of P-DAS and P-Epi
[0067] 1. Experimental Methods
[0068] (I) Synthesis of functionalized methacrylate monomers
[0069] 1. Preparation of MA-PEG5-Lys(G2)-4Alkynyl
[0070] (1) Preparation of MA-PEG5-NHBoc
[0071] A dichloromethane (DCM) solution of N-tert-butyloxycarbonyl-pentapolyethylene glycol-amino (BocNH-PEG5-NH2, CAS: 189209-27-6 0.38 g, 1.00 mmol, 1.0 eq) was added to a 100 mL flask, and then triethylamine (Et3N) (0.30 g, 3.00 mmol, 3.0 eq) was added under ice bath conditions, and finally methacryloyl chloride (0.16 g, 1.50 mmol, 1.5 eq) was slowly added using a dropping funnel. After 4 hours, the reaction solution was removed by a rotary evaporator, and the residue was purified by column chromatography, and the mobile phase was dichloromethane (DCM) / methanol (MeOH) (v / v, 100 / 1-20 / 1). 0.40 g of colorless oily liquid MA-PEG5-NHBoc was obtained with a yield of 83%.
[0072] (2) Preparation of MA-PEG5-NH2·TFA
[0073] MA-PEG5-NHBoc (0.90 g, 2.00 mmol) was placed in a flask, and then 2 mL of DCM was added. 2 mL of trifluoroacetic acid (TFA) was added to the flask at 0°C. The reaction was monitored by thin layer chromatography (TLC). After the reaction was completed, DCM and TFA were removed by rotary evaporation, and DCM was added and the solvent was removed by rotary evaporation. This was repeated three times to remove the residual TFA in the product. The product, MA-PEG5-NH2·TFA, was used directly without further purification.
[0074] (3) Preparation of MeO-Lys(G2)-4Alkynyl
[0075] ① Preparation of MeO-Lys(G2)-4NH2·TFA
[0076] Weigh Boc-Lys(OH)-Boc (CAS: 2483-46-7, 18.562 g, 53.615 mmol, 2.5 eq) in a 500 mL round-bottom flask, add 400 mL DMF to dissolve. Slowly add EDCI (CAS: 7084-11-9, 16.444 g, 85.784 mmol, 4.0 eq), HOBt (CAS No. 2592-95-2, 11.591 g, 85.784 mmol, 4.0 eq), MeO-Lys-NH2·HCl (CAS: 67396-08-1, 5.000 g, 21.446 mmol, 1.0 eq) under nitrogen protection, and add 21 mL DIPEA (CAS: 7087-68-5, 16.631 g, 128.676 mmol, 6.0 eq) under ice-salt bath conditions. Slowly warm to room temperature overnight to react. After the reaction is completed, add the reaction solution to a saturated NaHCO3 solution, add ethyl acetate (EA) for extraction, and wash the EA phase with saturated NaHCO3 (3×500mL), 1M HCl (3×500mL), and saturated NaCl (2×500mL) in sequence, dry with anhydrous Na2SO4, and evaporate by rotary evaporation. A yellow oily liquid is obtained, and column chromatography (DCM / EA=1:1) yields 17.57g of white solid MeO-Lys(G2)-NHBoc, with a yield of 99%.
[0077] Weigh 2.978g MeO-Lys(G2)-4NHBoc into a 100mL round-bottom flask, add 11mL dichloromethane (DCM) to dissolve, place the round-bottom flask in an ice-water bath, add 11mL TFA after 10min, install a liquid seal, continue stirring in the ice-water bath for 30min, and then move to room temperature to react overnight. After the reaction is completed, remove TFA by rotary evaporation, and use DCM to evaporation three times (3×100mL), and pump dry with an oil pump to prepare MeO-Lys(G2)-4NH2·TFA.
[0078] ② Preparation of MeO-Lys(G2)-4Alkynyl
[0079] 5-Hexynoic acid (2.45 g, 21.88 mmol, 6.0 eq), HBTU (CAS: 94790-37-1, 11.06 g, 29.18 mmol, 8.0 eq) and HOBt (CAS: 2592-95-2, 3.94 g, 29.18 mmol, 8.0 eq) were weighed into a 500 mL flask, and 200 mL of dimethylformamide (DMF) was added at 0°C. Under nitrogen protection, a DMF solution (50 mL) of MeO-Lys(G2)-4NH2·TFA (3.65 mmol, 1.0 eq) was added to the flask. Finally, 9.6 mL of DIPEA (CAS: 7087-68-5, 7.54 g, 58.35 mmol, 16.0 eq) was added. After stirring at room temperature for 24 hours, the reaction was quenched with water and extracted with ethyl acetate (EA), and then washed with saturated sodium bicarbonate (250 mL × 3), 1M dilute hydrochloric acid (250 mL × 3), saturated sodium chloride solution (250 mL × 3), and finally dried over anhydrous sodium sulfate. EA was removed by rotary evaporation, and the residue was purified by column chromatography with DCM / MeOH (v / v, 40 / 1) as the mobile phase to obtain 2.68 g of yellow solid product MeO-Lys(G2)-4Alkynyl with a yield of 92%.
[0080] (4) Preparation of MA-PEG5-Lys(G2)-4Alkynyl
[0081] ① Preparation of HO-Lys(G2)-4Alkynyl
[0082] MeO-Lys(G2)-4Alkynyl (1.96 g, 2.47 mmol, 1.0 eq) was added to a 50 mL flask and dissolved in 10 mL MeOH. 10 mL of an aqueous solution of NaOH (0.50 g, 12.37 mmol, 5.0 eq) was added to the flask at 0°C. After 10 minutes, the flask was moved to room temperature. TLC was used to monitor the progress of the reaction. After the reaction was completed, MeOH was removed by rotary evaporation, and 1 M dilute hydrochloric acid was added to adjust the pH to about 2. A white solid was precipitated, which was filtered and dried in vacuo to obtain the product HO-Lys(G2)-4Alkynyl.
[0083] ② Preparation of MA-PEG5-Lys(G2)-4Alkyny
[0084] HO-Lys(G2)-4Alkynyl (0.35 g, 0.45 mmol, 1.0 eq), HBTU (0.25 g, 0.67 mmol, 1.5 eq) and HOBt (0.09 g, 0.67 mmol, 1.5 eq) were dissolved in 10 mL DMF at 0°C, and 5 mL of MA-PEG5-NH2·TFA (0.45 mmol, 1.0 eq) in DMF was added under nitrogen. Finally, DIPEA (0.23 g, 1.78 mmol, 4.0 eq) was slowly added to the reaction mixture. After the reaction was completed, 250 mL of H2O and EA were added, and then washed with saturated sodium bicarbonate (250 mL×3), 1 M dilute hydrochloric acid (250 mL×3), saturated sodium chloride solution (250 mL×3), and finally dried over anhydrous sodium sulfate. The solid was removed by filtration, and the solution was concentrated under vacuum to obtain a crude product. The white solid was purified by column chromatography using DCM / MeOH (v / v, 20 / 1-10 / 1) as the mobile phase to obtain 2.64 g of yellow solid MA-PEG5-Lys(G2)-4Alkynyl with a yield of 86%. The synthetic route of compound MA-PEG5-Lys(G2)-4Alkynyl is as follows: Figure 1 As shown in (1)-(4), the H NMR spectrum of MA-PEG5-Lys(G2)-4Alkynyl is as follows Figure 2 shown.
[0085] 2. Preparation of MA-PEG5-Lys(G2)-4SSPy
[0086] (1) MA-PEG5-Lys(G2)-4NHBoc
[0087] ① Preparation of HO-Lys(G2)-4NHBoc
[0088] Weigh MeO-Lys(G2)-NHBoc (2.520 g, 3.08 mmol, 1.0 eq) in a 100 mL round-bottom flask and add 10 mL of methanol. Add sodium hydroxide (0.616 g, 15.40 mmol, 5.0 eq) aqueous solution (10 mL) under ice-water bath conditions, slowly warm to room temperature and stir to react. Monitor the progress of the reaction by TLC. After the reaction is completed, remove methanol by rotary evaporation, add hydrochloric acid to adjust pH to 1, add 200 mL of ethyl acetate for extraction, remove most of the water from the organic phase with saturated NaCl, dry over anhydrous sodium sulfate, remove the organic solvent by rotary evaporation, and dry to obtain HO-Lys(G2)-4NHBoc (2.352 g white solid), yield = 95%.
[0089] ② Preparation of MA-PEG5-Lys(G2)-4NHBoc
[0090] HO-Lys(G2)-4NHBoc (2.37 g, 2.96 mmol, 1.0 eq), HBTU (1.68 g, 4.44 mmol, 1.5 eq) and HOBt (0.60 g, 4.44 mmol, 1.5 eq) were added to a 100 mL flask and dissolved in 30 mL DMF at 0°C. Under nitrogen protection, 20 mL of DMF solution of MA-PEG5-NH2·TFA (32.96 mmol, 1.0 eq) was added to the flask. Finally, 1.5 mL of DIPEA (1.15 g, 8.87 mmol, 3.0 eq) was added. The EA phase was washed with saturated sodium bicarbonate (250 mL×3), 1 M dilute hydrochloric acid (250 mL×3), and saturated sodium chloride solution (250 mL×3) in sequence, and finally dried over anhydrous sodium sulfate to obtain MA-PEG5-Lys(G2)-4NHBoc. The organic solution was removed by rotary evaporation and the residue was purified by column chromatography with DCM / MeOH (v / v, 50 / 1-20 / 1) as the mobile phase to obtain 1.67 g of yellow liquid with a yield of 50%.
[0091] (2) Preparation of MA-PEG5-Lys(G2)-4SSPy
[0092] Py-SS-COOH (0.44 g, 2.07 mmol, 6.0 eq), HBTU (1.04 g, 2.75 mmol, 8.0 eq) and HOBt (0.36 g, 2.75 mmol, 8.0 eq) were added to a 50 mL flask and dissolved in 10 mL DMF at 0°C. Under nitrogen protection, 10 mL of DMF solution of MA-PEG5-NH2·TFA (0.34 mmol, 1.0 eq) was added to the flask. Finally, 0.2 mL of DIPEA (0.16 g, 5.50 mmol, 16.0 eq) was added. The EA phase was washed with saturated sodium bicarbonate (250 mL×3), 1 M dilute hydrochloric acid (250 mL×3), and saturated sodium chloride solution (250 mL×3) in sequence, and then dried over Na2SO4. The organic solvent was removed by rotary evaporation. The precipitated solid was filtered and then vacuum dried to obtain 0.25 g of white solid MA-PEG5-Lys(G2)-4SSPy with a yield of 47.2%. The synthetic route of compound MA-PEG5-Lys(G2)-4SSPy is as follows: Figure 1 As shown in (5)-(6), the SSPy H NMR spectrum of MA-PEG5-Lys(G2)-4 is as follows Figure 3 Show.
[0093] (II) Synthesis of N3-GFLG-DAS
[0094] N3-GFLG-COOH (1.32 g, 2.49 mmol, 1.2 eq) was added to a 25 mL flask, and 10 mL DMF was added at room temperature. After dissolution, dicyclohexylcarbodiimide (DCC) (2.56 g, 12.29 mmol, 5.0 eq) and 4-dimethylaminopyridine (DMAP) (0.75 g, 6.15 mmol, 2.5 eq) were added to the flask in sequence. Finally, dasatinib (DAS) (1.00 g, 2.05 mmol, 1.0 eq) was added to the flask. The reaction was stopped after 24 hours, and 200 ml of water and EA were added, and the liquids were separated. Then, the liquids were washed with saturated sodium bicarbonate (250 mL × 3) and saturated sodium chloride solution (250 mL × 3) in sequence, and finally dried with Na2SO4. EA was removed by rotary evaporation to precipitate solids. Filter, wash the solids with EA several times, and then vacuum dry. 1.79 g of white solid N3-GFLG-DAS was obtained with a yield of 87%. The H NMR spectrum of compound N3-GFLG-DAS is as follows Figure 5 shown.
[0095] (III) Synthetic dendrimers (POEGMA-4Alkynyl and POEGMA-4SSPy)
[0096] 1. Synthesis of POEGMA-4Alkynyl
[0097] The synthetic routes of POEGMA-4Alkynyl and POEGMA-4SSPy are as follows Figure 6 shown.
[0098] OEGMA (1.31 g, 2.61 mmol), 4-cyano-4-(thiobenzoyl) valeric acid (CTA, CAS: 201611-92-9, 14.00 mg, 50.17 μmol), MA-PEG5-Lys(G2)-4Alkynyl (0.14 g, 122.67 μmol) and initiator 4,4'-azobis(4-cyanovaleric acid) (ACVA, CAS: 2638-94-0, 5.60 mg, 20.00 μmol) were dissolved in 6.55 mL of a mixed solvent of dimethyl sulfoxide (DMSO) / H2O (v / v, 9 / 1), argon was replaced for 50 min, and then stirred at 72°C in the dark for 18 hours. After the reaction, the reaction solution was dialyzed with deionized water for 48 hours (molecular weight cutoff: 8 kDa). After freeze drying, 1.37 g of POEGMA-4Alkynyl was obtained with a yield of 94%. The H NMR spectrum of the compound POEGMA-4Alkynyl is as follows Figure 7 shown.
[0099] 2. Synthesis of POEGMA-4SSPy
[0100] OEGMA (1.355 g, 2.71 mmol), CTA (12.6 mg, 45.09 μmol), MA-PEG5-Lys (G2) -4SSPy (0.151 g, 99.35 μmol) and initiator 4,4'-azobis (4-cyanovaleric acid) (ACVA, CAS: 2638-94-0, 5.0 mg, 18.00 μmol) were dissolved in 6.15 mL of a mixed solvent of dimethyl sulfoxide (DMSO) / H2O (v / v, 9 / 1), argon was replaced for 50 min, and then stirred at 72 ° C in the dark for 18 hours. After the reaction, the reaction solution was dialyzed with deionized water for 48 hours (molecular weight cutoff: 8 kDa). After freeze drying, 1.50 g of POEGMA-4Alkynyl was obtained with a yield of 99%. The H NMR spectrum of the compound POEGMA-4SSPy is as follows Figure 8 shown.
[0101] (IV) Synthesis of dendrimer copolymer-drug conjugates P-DAS and P-Epi
[0102] The synthetic routes of compound P-DAS and compound P-Epi are as follows Fig. 9 shown.
[0103] 1. Preparation of P-DAS
[0104] POEGMA-4Alkynyl (0.90 g), N3-GFLG-DAS (0.26 mg, 260.34 μmol) and CuSO4·5H2O (0.14 g, 567.40 μmol) were dissolved in a mixed solvent of 10 mL DMSO / H2O (v / v, 9 / 1). After the mixture was bubbled with nitrogen for 30 minutes, an aqueous sodium ascorbate solution (0.22 g, 1.13 mmol) was added to the mixture. After reacting for 24 hours, the reaction solution was dialyzed with deionized water for 48 hours (molecular weight cutoff: 8 kDa). After filtration and freeze drying, 0.87 g of product P-DAS was obtained with a yield of 75%. The H NMR spectrum of compound P-DAS is shown in Fig.10 As shown. In the P-DAS structure, x is 45-52 and y is 0.5-2.5.
[0105] 2. Preparation of Mal-Epi
[0106]
[0107] Weigh Mal-NH-NH2·HCl (CAS: 293298-33-6) (193 mg, 0.690 mmol, 2.0 eq) and Epi (CAS: 56420-45-2) (200 mg, 0.345 mmol, 1.0 eq) in a 25 mL round-bottom flask and add 10 mL of MeOH. After dissolution, add a catalytic amount of TFA (20 μL). React at room temperature in the dark for 24 hours. After the reaction is completed, the reaction is also dripped into a mixed solvent of TFA / ether (v / v=1 / 1), and a large amount of red solid is precipitated and filtered. The red solid is washed several times with TFA / ether (v / v=1 / 1) and vacuum dried to obtain 250 mg of Mal-Epi red solid with a yield of 97.6%.
[0108] 3. Preparation of P-Epi of the present invention
[0109] POEGMA-4SSPy (0.44 g) and TCEP (CAS: 5961-85-3, 0.44 g) were dissolved in 5 mL of water. The reaction was stirred at room temperature for 0.5 hours, and then the mixture was transferred to a dialysis bag (molecular weight cutoff: 8 kDa) and dialyzed with deionized water for 8 hours. The resulting solution was placed in a flask, and then 10 mL of Mal-Epi (0.17 g) DMSO solution was added to the flask under an ice bath. Finally, a drop of triethylamine was added to catalyze the reaction. After 24 hours, the reaction solution was dialyzed with deionized water for 24 hours (molecular weight cutoff: 8 kDa). After filtration and freeze-drying, 0.42 g of P-Epi was obtained with a yield of 83%. The P-Epi H NMR spectrum is shown in Fig.11 As shown. In the P-Epi structure, m is 50-60 and n is 0.5-2.2.
[0110] The beneficial effects of the present invention are demonstrated by experimental examples below.
[0111] Experimental Example 1: P-DAS of the present invention Cy5 Weight average molecular weight (Mw) and number average molecular weight (Mn) and drug loading of P-DAS and P-Epi
[0112] 1. Experimental Methods
[0113] 1. Use Gel Permeation Chromatography (GPC)
[0114] The weight average molecular weight (Mw) and number average molecular weight (Mn) of the polymer were detected. The mobile phase was a mixed solution of 0.2M lithium chloride and DMF (v / v=35 / 65) at a flow rate of 0.5 mL / min. Polyethylene glycol (PEG) of different molecular weights was used as the standard.
[0115] 2. UV-Vis spectroscopy
[0116] The DAS content in P-DAS was detected by UV-visible spectroscopy (UV1800ENG240V, SOFT, Shimadzu, Japan). DAS was dissolved in DMSO and diluted to different concentrations (20, 10, 5, 2.5, 1.25 and 0.625 μg / mL). A standard curve for DAS was established based on the absorbance at 325 nm of a given concentration. P-DAS was dissolved in 250 μg / mL of DMSO, and the absorbance value of P-DAS at 325 nm was obtained, and the drug content was calculated based on the standard curve of DAS. The calculation formula for DAS drug loading is (mass of DAS in P-DAS / mass of P-DAS) × 100%.
[0117] The standard curve of N3-Cy5 was constructed based on the absorbance of N3-Cy5 at 641 nm at different concentrations (5, 2.5, 1.25, 0.63, 0.31 and 0.16 μg / mL). Cy5 The content of Cy5 in P-DAS. Cy5 P-DAS was dissolved in DMSO at a concentration of 500 μg / mL. Cy5 The absorbance value of P-DAS at 641nm was used to calculate the drug loading according to the standard curve of N3-Cy5. The calculation formula of Cy5 drug loading is ( Cy5 The mass of Cy5 in P-DAS / Cy5 mass of P-DAS)×100%.
[0118] Similarly, the content of Epi in P-Epi was detected by UV-visible spectroscopy. Epi was dissolved in DMSO and then diluted to different concentrations (100, 50, 25, 12.5, 6.25 and 3.125 μg / mL). A standard curve for Epi was established based on the absorbance value at 480 nm at a given concentration. P-Epi was dissolved in DMSO at a concentration of 1 mg / mL, the absorbance value of P-Epi at 480 nm was obtained, and the drug loading was obtained based on the standard curve of Epi. The calculation formula for the drug loading of Epi is (the mass of Epi in P-Epi / the mass of P-Epi) × 100%.
[0119] 2. Experimental Results
[0120] With POEGMA-4Alkynyl (26.6 kg mol -1 ) and POEGMA-4SSPy (26.2 kg mol -1 ), the weight-average molecular weights (Mw) of P-DAS and P-Epi increased to 38.5 kg mol -1 and 39.7 kg mol -1Similar to free DAS, the maximum absorption peaks of N3-GFLG-DAS and P-DAS in DMSO solution are at 325 nm ( Fig.12 ), similarly, Mal-Epi and P-Epi showed UV absorption similar to that of free Epi ( Fig.13 ), indicating that covalent coupling of DAS or Epi to the polymer does not affect its spectroscopic properties. According to the standard curves of DAS and Epi, the mass content of DAS in P-DAS is 5.5% ( Fig.14 ), the mass content of Epi in P-Epi is 6.9% ( Fig.15 ).
[0121] Experimental Example 2: Hydration Particle Size, Zeta Potential and Morphology of P-DAS and P-Epi
[0122] 1. Experimental Methods
[0123] P-DAS and P-Epi nanoparticles were prepared by ultrasound. The hydrated particle size and zeta potential of P-DAS and P-Epi were measured by dynamic light scattering (DLS, Brookhaven, USA).
[0124] 2. Experimental Results
[0125] P-DAS and P-Epi self-assemble into nearly neutral nanoparticles in water ( Fig.16 ), the hydrated particle sizes of P-DAS and P-Epi were 70.9±8.4nm and 147.6±21.3nm, respectively ( Fig.17 ).
[0126] Experimental Example 3 Sequential combination of P-DAS and P-Epi to stimulate DC maturation and cytokine secretion in vitro
[0127] 1. Experimental Methods
[0128] Sequential combined therapy induced dendritic cells (DCs) maturation in vitro. Bone marrow derived dendritic cells (BMDCs) were isolated from the femur and tibia of 4-week-old Balb / c mice. The cell pellet after centrifugation of the bone marrow was dispersed in red blood cell lysis buffer and centrifuged again at 1500 rpm for 5 minutes. The cells were placed in RPMI 1640 medium containing 10% inactivated fetal bovine serum, 100 U / ml penicillin, 100 U / ml streptomycin, 20 ng / ml GM-CSF and 10 ng / ml IL-4, and immature BMDCs were obtained after incubation for 7 days.
[0129] 4T1 cells were inoculated in confocal microplates and cultured overnight. The following dosing regimens were used: Control group, P-DAS group, P-Epi group and P-DAS→P-Epi group, where Control group means no drug administration, P-DAS group means only P-DAS administration (dosing concentration is 1 μg / mL calculated according to DAS), P-Epi group means only P-Epi administration (dosing concentration is 1 μg / mL calculated according to Epi), and P-DAS→P-Epi group means first administration of P-DAS (dosing concentration is 1 μg / mL calculated according to DAS) and then administration of P-Epi (dosing concentration is 1 μg / mL calculated according to Epi).
[0130] After 24 hours of treatment of 4T1 cells, the supernatants of different dosing regimens were collected and co-cultured with immature BMDCs for 24 hours. After the cells were collected, they were stained with anti-CD11c, anti-MHC II, anti-CD80 and anti-CD86, and mature DCs were detected by flow cytometry. In addition, the secretion of interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) in the supernatant of BMDCs was detected by ELISA kits.
[0131] 2. Experimental Results
[0132] Mouse bone marrow-derived dendritic cells (BMDCs) were used to express CD11c + MHC II + CD80 + CD86 + The ratio of cell subsets was used to quantitatively evaluate the level of DCs maturation induced by 4T1 cell supernatant after different treatments. Compared with the control group, the DCs maturation in the P-Epi treatment group increased significantly to about 22.8%. After P-DAS→P-Epi treatment, the DCs maturation increased to 25.3% ( Fig.18 and Fig.19 ). Mature DCs release proinflammatory cytokines for immune activation, such as TNF-α and IFN-γ. Compared with other groups, the levels of TNF-α and IFN-γ secreted by DCs in the P-Epi group and the P-DAS→P-Epi group were significantly increased, which is consistent with the results of DC maturation. Therefore, P-DAS→P-Epi can effectively induce ICD in 4T1 cells, stimulate DCs maturation, and improve anti-tumor immunity.
[0133] Experimental Example 4: In vitro antitumor effect of sequential combination of P-DAS and P-Epi
[0134] 1. Experimental Methods
[0135] 1. CCK-8 method to detect cell activity
[0136] Cytotoxicity: The cytotoxicity of free DAS, free Epi and their polymer nanoparticles (P-DAS and P-Epi) on 4T1 cells was evaluated by CCK-8 method.
[0137] In the following experiments, the basal medium was RPMI 1640 containing 10% serum, and the serum-free medium was RPMI 1640.
[0138] For DAS-based monotherapy, 4T1 cells were seeded in 96-well plates, and the basal medium was replaced with drug-containing medium (basal medium containing DAS and P-DAS) after overnight culture. The drug-containing medium of each experimental group contained different concentrations of DAS (0.001, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 5 μg / mL). After 24 hours of culture, the drug-containing medium was removed and replaced with fresh basal medium without drug and cultured for another 24 hours.
[0139] For Epi-based monotherapy, 4T1 cells were inoculated in 96-well plates, and the basal medium was replaced with fresh basal medium without drugs after overnight culture. After 24 hours of culture, the basal medium was replaced with drug-containing medium containing different concentrations of Epi and P-Epi. The drug-containing medium of each experimental group contained different concentrations of Epi (0.001, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 5 μg / mL) and continued to be cultured for 24 hours. The cells were washed 3 times with PBS, serum-free medium containing 10% CCK-8 was added, incubated for 1.5 hours, and then the absorbance value of the cells at 450nm was measured with an ELISA instrument to calculate the relative cell viability. The cell survival rate is the percentage relative to the cell survival rate of the control group.
[0140] The cytotoxicity of sequential combination of P-DAS and P-Epi (P-DAS→P-Epi) in 4T1 cells was evaluated by CCK-8 method. Sequential combination of different DAS / Epi mass ratios (1:2, 1:1 and 2:1) was used for sequential administration. 4T1 cells were seeded in 96-well plates. After overnight culture, P-DAS containing 0.001, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, and 5 μg / mL DAS was added and incubated with cells for 24 hours. The culture medium was replaced with drug-containing culture medium containing different concentrations of free Epi and P-Epi, and culture was continued for 24 hours. The cells were washed 3 times with PBS, serum-free culture medium containing 10% CCK-8 was added, incubated for 1.5 hours, and then the absorbance value of the cells at 450nm was measured with a microplate reader to calculate the relative cell viability. The cell survival rate is the percentage relative to the cell survival rate of the control group. The combination index (CI) was calculated using Compusyn.
[0141] 2. Annexin V-FITC / PI kit staining experiment
[0142] Apoptosis: 4T1 cells were inoculated in 12-well plates and cultured overnight. The following dosing regimens (Control, DAS, Epi, DAS→Epi, P-DAS, P-Epi, and P-DAS→P-Epi) were used for incubation. The incubation method was the same as that used in the above-mentioned CCK-8 kit to detect the in vitro cytotoxicity of P-DAS on 4T1 cells, where the concentrations of DAS and Epi were 0.5 μg / mL. The cells were digested and collected using trypsin, stained using the Annexin V-FITC / PI kit, and finally detected by flow cytometry.
[0143] 3. Clone formation experiment
[0144] 4T1 cells were inoculated in 6-well plates for overnight culture, and the dosing regimens (Control, DAS, Epi, DAS→Epi, P-DAS, P-Epi, and P-DAS→P-Epi) were used for incubation, respectively, and the incubation method was the same as the above-mentioned CCK-8 kit for detecting the in vitro cytotoxicity of P-DAS on 4T1 cells, wherein the DAS concentration was 0.1 and 0.2 μg / mL, and the Epi concentration was 0.1 and 0.2 μg / mL. After 4 days of culture, the cells were fixed with 4% paraformaldehyde, stained with crystal violet, washed with PBS, and photographed after drying.
[0145] 2. Experimental Results
[0146] 1. CCK-8 method experimental results
[0147] The CCK-8 method was used to study the antitumor effect of P-Epi in vitro. Fig. 20 (When the mass ratio of DAS / Epi is 1:0, Fig. 20 The horizontal axis is the concentration of DAS in P-DAS. When the mass ratio of DAS / Epi is 2:1, 1:1, 1:2 and 0:1, Fig. 20 The horizontal axis in the figure is the concentration of Epi in P-Epi. It can be seen that the survival rate of 4T1 cells is negatively correlated with the concentration of P-Epi, and the half inhibitory concentration (IC 50 ) was 1.5 μg / mL. In addition, the CCK-8 method was used to study the in vitro antitumor effect of sequential combination of P-DAS and P-Epi (P-DAS→P-Epi) therapy under different mass ratios of DAS and Epi. The combination index (CI) of sequential combination therapy was calculated using CompuSyn software. When the mass ratio of DAS / Epi was 1:1, the CI value was the lowest, which was used as the optimal combination ratio of P-DAS→P-Epi ( Fig.21 , the horizontal axis is the concentration of Epi in P-Epi).
[0148] 2. Annexin V-FITC / DAPI kit test results
[0149] Annexin V-FITC / DAPI kit was used to detect the apoptosis of 4T1 cells induced by P-DAS→P-Epi. Flow cytometry analysis showed that the apoptosis rates of 4T1 cells treated with DAS and Epi were approximately 44.0% and 18.1%, respectively, and those treated with P-DAS and P-Epi were 21.7% and 31.9%, respectively. The apoptosis rates of 4T1 cells in the DAS→Epi group were 52.0%, and those in the P-DAS→P-Epi group were 47.7%.
[0150] 3. Results of clone formation experiments
[0151] The clone formation assay is an effective method to determine the proliferation ability of single cells and can be used to evaluate the long-term therapeutic effect of P-DAS→P-Epi on 4T1 cells. When the concentrations of DAS and Epi were 0.1 μg / mL, the number of cell colonies in the P-DAS-treated group was equivalent to that in the control group, while P-Epi treatment significantly reduced the formation of cell colonies. Cell division was completely inhibited after P-DAS→P-Epi treatment. When the concentration of DAS or Epi was increased to 0.2 μg / mL, the inhibitory effect was more obvious. Therefore, the sequential combination of P-DAS and P-Epi can significantly induce cell apoptosis and inhibit cell proliferation.
[0152] The experimental results showed that P-DAS and P-Epi had excellent anti-tumor effects, and the combination of P-DAS and P-Epi had a synergistic effect, and the best synergistic effect was achieved when the mass ratio of DAS / Epi was 1:1. Therefore, the sequential combination of P-DAS and P-Epi can significantly induce cell apoptosis and inhibit tumor cell proliferation.
[0153] Experimental Example 5 Animal Experiment
[0154] 1. Experimental Methods
[0155] (I) Experimental groups
[0156] 1. Animal modeling
[0157] All animal experiments were performed in accordance with the guidelines of the Animal Ethics Committee of West China Hospital of Sichuan University. 5 4T1 cells were resuspended in 50 μL PBS and inoculated subcutaneously on the right flank of 6-week-old female Balb / c mice. 3 When the mice are treated with tumours, they can be used for tumour therapy experiments.
[0158] 2. Experimental Grouping
[0159] When the tumor grows to 70 mm 3 At about 14:00 p.m., the mice were randomly divided into 9 groups, namely: saline group, DAS group, Epi group, DAS→Epi group, P-DAS group, P-Epi group, P-DAS→P-Epi group, each group had 15 mice, and anti-PD-1 antibody group and P-DAS→P-Epi combined with anti-PD-1 antibody group had 10 mice in each group, wherein the dose of DAS and EPI was 8 mg / kg (the dose of DAS in each injection of DAS-containing drug in DAS group, DAS→Epi group, P-DAS group, P-DAS→P-Epi group was 8 mg / kg; the dose of Epi in each injection of Epi-containing drug in Epi group, DAS→Epi group, P-Epi group, P-DAS→P-Epi group was 8 mg / kg). The formula containing DAS was injected into the tail vein on days 1, 3, 5 and 7, and the formula containing Epi was injected intravenously on days 4 and 8. On days 4 and 8, mice were intraperitoneally injected with anti-PD-1 antibody, with each injection of anti-PD-1 antibody at a dose of 5 mg / kg. The tumor volume and body weight of the mice were monitored every other day.
[0160] On the 19th day, 5 mice in each group were killed, and their main organs and tumor tissues were obtained for histological examination, which were performed by hematoxylin and eosin (H&E) staining, terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick-endlabeling (TUNEL) staining, immunohistochemical staining (CD31, Ki67, α-SMA and fibronectin), and Masson's trichrome collagen staining.
[0161] The remaining mice continued to monitor the tumor volume and body weight every other day. For the survival study, after the completion of treatment, the 4T1 tumor-bearing mice were continuously monitored and recorded, and euthanized after reaching the experimental endpoint. 3 Or the mice's body weight decreased by more than 20% was considered to have reached the experimental endpoint.
[0162] 3. Data Analysis
[0163] All experimental data of the present invention are presented in the form of mean ± standard deviation, and the number of samples in each group is greater than or equal to 3 (n ≥ 3). This paper uses GraphPad Prism 8 to analyze the significant differences between independent samples of different groups. The analysis method adopts the two-tailed t-test method, and P < 0.05 is defined as a significant difference between the two groups.
[0164] 2. Experimental Results
[0165] For example, the anti-tumor curve of 4T1 tumor-bearing mice Fig. 22 and tumor inhibition rate on day 19 Fig.23 As shown in the figure, the tumor volume of mice in the saline group and the DAS group increased rapidly, approaching 1500 mm on the 19th day. 3 Epi and DAS→Epi had a certain inhibitory effect on tumor growth, but the tumor volume still increased to 1000mm 3 There was no synergistic effect between DAS and Epi when administered in free form. Fig.23 It can be seen that the tumor inhibition rates of P-DAS and P-Epi were greater than those of DAS and Epi, respectively. The tumor volume of mice in the P-DAS→P-Epi group was the smallest, and the tumor inhibition rate of the P-DAS→P-Epi group was significantly higher than that of P-DAS, P-Epi, and DAS→Epi. At the same time, the combined use of P-DAS and P-Epi had the best tumor inhibition effect.
[0166] The results of H&E, CD31, Ki67, and TUNEL staining showed that after P-DAS→P-Epi treatment, the number of abnormal cells in the tumor site increased, angiogenesis decreased, proliferation was inhibited, and apoptosis increased, indicating that P-DAS→P-Epi treatment had a good antitumor effect in vivo.
[0167] In addition, the expression of α-SMA in the tumor site was reduced after P-DAS or P-DAS→P-Epi treatment, and the deposition levels of fibronectin and collagen were also reduced, which may be due to the reversal of the CAFs phenotype, resulting in a decrease in their secretory protein levels. + P-Epi treatment caused CRT exposure in tumor tissues, and after P-DAS→P-Epi treatment, CRT exposure was further enhanced. Compared with P-Epi treatment, CD8 + The infiltration of T lymphocytes was more obvious. Therefore, P-DAS can reverse the CAFs type and reduce ECM deposition, paving the way for P-Epi to enhance anti-tumor immunity. The results of lung H&E staining showed that after P-DAS→P-Epi treatment, lung metastasis was significantly reduced, indicating that it has a strong inhibitory effect on tumor proliferation and lung metastasis ( Fig.24 During the treatment, the mice in the Epi and DAS→Epi groups lost significant weight, while no weight loss was observed in the other groups. After P-DAS→P-Epi treatment, no pathological damage was observed in the heart, liver, spleen, or kidneys, indicating that this treatment method is effective and safe.
[0168] P-DAS→P-Epi was used in combination with anti-PD-1 antibodies to enhance the effect of immunotherapy. Tumors in mice treated with a single anti-PD-1 antibody grew rapidly, but after combined treatment with P-DAS→P-Epi, its anti-tumor effect was significantly enhanced ( Fig.25 At the end of treatment, the TGI of anti-PD-1 antibody was approximately 7.5%, while the TGI of P-DAS→P-Epi+anti-PD-1 antibody increased to 84.0% ( Fig.26 In addition, mice treated with saline and anti-PD-1 antibody died on days 26 and 29, respectively, while 5 out of 10 mice treated with P-DAS→P-Epi+anti-PD-1 antibody survived on day 39, with a survival rate of 50% ( Fig. 27 During the treatment, the body weight of all experimental mice did not decrease. P-DAS→P-Epi+anti-PD-1 treatment did not damage liver, heart and kidney function, indicating that the combined treatment did not cause obvious systemic toxicity ( Fig.28 ).
[0169] The above experimental results show that the combination of P-DAS and P-Epi has a synergistic anti-tumor effect. In addition, the combination of P-DAS, P-Epi and anti-PD-1 antibodies can further enhance the synergistic anti-tumor effect.
[0170] In summary, the present invention provides a dendrimer-based nanomedicine and its application. The present invention combines DAS and Epi with different dendrimers respectively to synthesize two nanomedicines P-DAS and P-Epi. The P-DAS and P-Epi prepared by the present invention significantly improve the inhibition of cancer cell proliferation by DAS and Epi. At the same time, when P-DAS is used in combination with P-Epi, the tumor inhibition effect in vivo is more excellent, and tumor metastasis can be inhibited at the same time. When P-DAS, P-Epi and anti-PD-1 antibodies are used in combination, the tumor inhibition effect in vivo is further improved, and there is no obvious toxic side effect. The present invention has excellent application prospects in inhibiting breast cancer tumors and inhibiting tumor metastasis.
Claims
1. A dasatinib dendrimer drug, characterized in that: Its structure is shown in Formula I: Among them, x is 30-60; y is 0.1-5; The content of dasatinib in the dasatinib dendrimer drug is 3-10 wt %.
2. The dasatinib dendrimer drug according to claim 1, characterized in that: The weight average molecular weight of the dasatinib dendrimer drug is 30-45 kg mol -1 , x is 45-52, y is 0.5-2.5, and the content of dasatinib in the dasatinib dendrimer drug is 5.5wt%.
3. An epirubicin dendrimer drug, characterized in that: It is a product prepared by reacting the compound represented by formula II with tricarboxyethylphosphine and Mal-Epi in sequence; The structure of the compound shown in formula II is as follows: Wherein, m is 40-80; n is 0.1-4; The structure of Mal-Epi is as follows: The content of epirubicin in the epirubicin dendrimer drug is 3-12 wt %.
4. The epirubicin dendrimer prodrug according to claim 3, characterized in that: The weight average molecular weight of the epirubicin dendrimer drug is 30-45 kg mol -1 ; In the compound represented by formula II, m is 50-60, and n is 0.5-2.2; The mass ratio of the compound represented by formula II, tricarboxyethylphosphine, and Mal-Epi is 44:44:17; The reaction temperature is 20-35°C and the reaction time is 20-30 hours; The content of epirubicin in the epirubicin dendrimer drug is 6.9 wt%.
5. A combined drug with anti-tumor effect, characterized in that: It contains the dasatinib dendrimer drug according to any one of claims 1-2 and the epirubicin dendrimer drug according to any one of claims 3-4 for simultaneous or separate administration in unit preparations of the same or different specifications, and a pharmaceutically acceptable carrier; wherein the mass ratio of dasatinib in the dasatinib dendrimer drug to epirubicin in the epirubicin dendrimer drug is (1-2): (1-2).
6. The combined drug according to claim 5, characterized in that: The mass ratio of dasatinib in the dasatinib dendrimer drug to epirubicin in the epirubicin dendrimer drug is 1:
1.
7. The combined drug according to claim 5 or 6, characterized in that: It also contains anti-PD-1 antibodies in unit preparations of the same or different specifications for simultaneous or separate administration, wherein the mass ratio of the anti-PD-1 antibody to epirubicin in the epirubicin dendrimer drug is (3-10):(5-20).
8. The combined drug according to claim 7, characterized in that: The mass ratio of the anti-PD-1 antibody to epirubicin in the epirubicin dendrimer drug is 5:
8.
9. Use of the dasatinib dendrimer drug according to any one of claims 1 to 2, the epirubicin dendrimer drug according to any one of claims 3 to 4, and the combined drug according to any one of claims 5 to 8 in the preparation of drugs for treating tumors and / or inhibiting tumor metastasis.
10. The use according to claim 9, characterized in that The tumor is breast cancer.
